Presentation is loading. Please wait.

Presentation is loading. Please wait.

AHRQ QI Guide to Comparative Reporting AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Sheryl Davies.

Published byPriscilla Watson Modified over 8 years ago

Similar presentations

Presentation on theme: "AHRQ QI Guide to Comparative Reporting AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Sheryl Davies."— Presentation transcript:

1 AHRQ QI Guide to Comparative Reporting AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Sheryl Davies

2 Overview of document User tool to select indicators User tool to select indicators Indicators assigned to four tiers based on evidence Indicators assigned to four tiers based on evidence Gaps assessed for the following areas: Gaps assessed for the following areas: – Importance – Face Validity – Coding/Criterion Validity – Construct Validity – Risk Adjustment

3 Survey of Evidence Literature Literature – POA, coding validity, preventability, correlation with cost, LOS or other indicators, impact of QI programs AHRQ Validation Activities AHRQ Validation Activities – Chart review of coding validity – Clinical Panel Review National Quality Forum review National Quality Forum review Examination of potential improvements Examination of potential improvements

4 Tiers Tier 1: Minor or no evidence gaps Tier 1: Minor or no evidence gaps – 1B Serious reportable events Most suitable for comparative reporting/public accountability Most suitable for comparative reporting/public accountability Strongest evidence base Strongest evidence base Established evidence in several areas Established evidence in several areas No substantial evidence against use for comparative reporting No substantial evidence against use for comparative reporting Most endorsed by the National Quality Forum Most endorsed by the National Quality Forum

5 Tiers Tier 2: Moderate evidence gaps Tier 2: Moderate evidence gaps Users may choose to utilize these indicators for comparative reporting Users may choose to utilize these indicators for comparative reporting Some supporting evidence for use Some supporting evidence for use Some minor evidence gaps Some minor evidence gaps Indicator would be stronger with some additional evidence Indicator would be stronger with some additional evidence Most not currently endorsed by the National Quality Forum Most not currently endorsed by the National Quality Forum

6 Tiers Tier 3: Significant, but addressable, evidence gaps Tier 3: Significant, but addressable, evidence gaps Not currently suitable for comparative reporting, pending further development Not currently suitable for comparative reporting, pending further development At least one serious evidence gap or concern At least one serious evidence gap or concern Further development and validation work has been identified Further development and validation work has been identified Once further work is completed, indicators will be re-assigned to another tier Once further work is completed, indicators will be re-assigned to another tier Indicators not currently endorsed by NQF Indicators not currently endorsed by NQF

7 Tiers Tier 4: Significant evidence gaps Tier 4: Significant evidence gaps Substantial gaps in evidence for use in comparative reporting Substantial gaps in evidence for use in comparative reporting Gaps unlikely to be addressed with further development or validation Gaps unlikely to be addressed with further development or validation Not recommended for comparative reporting Not recommended for comparative reporting Indicators are not currently endorsed by NQF Indicators are not currently endorsed by NQF

8 Tier 1 Indicators IQIs IQIs – Esophageal Resection Volume (#01)* – Pancreatic Resection Volume (#02)* – Abdominal Aortic Aneurysm (AAA) Repair Volume (#04)* – Esophageal Resection Mortality (#08)* – Pancreatic Resection Mortality (#09)* – Abdominal Aortic Aneurysm (AAA) Repair Mortality (#11)* – AMI Mortality (#15 and #32) – CHF Mortality (#16)* – Acute Stroke Mortality (#17)* – Hip Fracture Mortality (#19)* – Pneumonia Mortality (#20)* – Incidental Appendectomy in the Elderly (#24)* – Bi-lateral Catheterization (#25)* *NQF endorsed

9 Tier 1 Indicators PDIs PDIs – Accidental Puncture or Laceration (#01)* – Decubitus Ulcer (#02)* – Iatrogenic Pneumothorax (#05)* – Pediatric Heart Surgery Mortality (#06)* – Pediatric Heart Surgery Volume (#07)* – Postoperative Wound Dehiscence (#11)* – Blood Stream Infection in Neonates (#02)* PSIs PSIs – Death among Surgical Inpatients with Treatable Serious Complications (#04)* – Iatrogenic Pneumothorax (#06)* – Postoperative Hip Fracture (#08) – Postoperative DVT or PE (#12)* – Postoperative Wound Dehiscence (#14)* – Accidental Puncture or Laceration (#15)* – OB Trauma with and without Instrument (#18 and #19) – Birth Trauma (#17)*

10 Tier 1B Indicators PSIs PSIs – Death in Low Mortality DRGs* – Transfusion Reaction* – Foreign Body Left in During Procedure* PDIs PDIs – Transfusion Reaction* – Foreign Body Left in During Procedure* *NQF endorsed

11 Tier 2 Indicators IQI IQI – Hip Replacement Mortality (#14) PDI PDI – Iatrogenic Pneumothorax in Neonates – Postoperative Hemorrhage or Hematoma (#08) – Postoperative Respiratory Failure (#09) – Postoperative Sepsis (#10) PSI PSI – Postoperative Hemorrhage or Hematoma (#09) – Postoperative Physiologic and Metabolic Derangement (#10) – Postoperative Respiratory Failure (#11) – Postoperative Sepsis (#13) *NQF endorsed

12 Tier 3 Indicators IQIs IQIs – CABG Mortality (#12) – Craniotomy Mortality (#13) – GI Hemorrhage Mortality (#18) PDIs/NQIs PDIs/NQIs – Hospital Acquired Vascular Catheter Related Infections (#12) – Neonatal Mortality PSIs PSIs – Decubitus Ulcer (#03) – Hospital Acquired Vascular Catheter Related Infections (#07)

13 Tier 4 Indicators IQIs IQIs – CABG Volume (#05) – PTCA Volume (#06) – Carotid Endarterectomy Volume (#07) – Cesarean Delivery (#21 and #33) – VBAC Delivery (#22 and #34) – Laparoscopic Cholecystectomy (#23) – PTCA Mortality (#30) – Carotid Endarterectomy Mortality (#31) PSIs PSIs – Complications of Anesthesia (#01) – OB Trauma-Cesarean Delivery (#20)

14 Applying Guidance to your Own Report Guidance document is a source of information, users need to weigh their own situation to select indicators Guidance document is a source of information, users need to weigh their own situation to select indicators AHRQ QI Reporting Template AHRQ QI Reporting Template Know your purpose Know your purpose – Tier 2 indicators may be more useful for some purposes than others

15 Applying Guidance to Your Own Support: Data Know your data Know your data – Potential data checks Rates and variation in POA Rates and variation in POA Procedure dates, Elective vs. Non-elective, E- codes Procedure dates, Elective vs. Non-elective, E- codes “Hospitals Like Mine” Tool – HCUPnet “Hospitals Like Mine” Tool – HCUPnet – AHRQ Tools Medical record review Medical record review u Audit u Individual hospitals

16 Questions?

Download ppt "AHRQ QI Guide to Comparative Reporting AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Sheryl Davies."

Similar presentations

Adverse Patient Safety Events: Costs of Readmissions and Patient Outcomes Following Discharge Didem M. Bernard, Ph.D. William E. Encinosa, Ph.D.

Adverse Patient Safety Events: Costs of Readmissions and Patient Outcomes Following Discharge Didem M. Bernard, Ph.D. William E. Encinosa, Ph.D.
Variations in Quality Outcomes Among Hospitals in Different Types of Health Systems, 1995 - 2000 Askar Chukmaitov, M.D., M.P.A. Askar Chukmaitov, M.D.,

Variations in Quality Outcomes Among Hospitals in Different Types of Health Systems, Askar Chukmaitov, M.D., M.P.A. Askar Chukmaitov, M.D.,
AHRQ IQI Clinical Validation Panels Sheryl Davies, MA Stanford University.

AHRQ IQI Clinical Validation Panels Sheryl Davies, MA Stanford University.
What Types of Websites and Reports Can MONAHRQ Generate? May 2014 Note: This is one of seven slide sets outlining MONAHRQ and its value, available at

What Types of Websites and Reports Can MONAHRQ Generate? May 2014 Note: This is one of seven slide sets outlining MONAHRQ and its value, available at
Hospital and Physician Outcomes Reports Presenter: Brian Paciotti, PhD.

Hospital and Physician Outcomes Reports Presenter: Brian Paciotti, PhD.
Evaluating the AHRQ Inpatient Mortality Indicators for Public Reporting in California AHRQ Users Meeting Joseph Parker, PhD Brian Paciotti, PhD Merry Holliday-Hanson,

Evaluating the AHRQ Inpatient Mortality Indicators for Public Reporting in California AHRQ Users Meeting Joseph Parker, PhD Brian Paciotti, PhD Merry Holliday-Hanson,
Session 3C: Overview of the AHRQ Quality Indicators Thursday, September 27, 2007 3:30 pm to 5:00 pm ET.

Session 3C: Overview of the AHRQ Quality Indicators Thursday, September 27, :30 pm to 5:00 pm ET.
IndicatorGoalHC?JulAugSepOctNovDecJanFebMarAprMayJunYTD % Perfection Worksite Safety Indicators Blood Borne Pathogen Exposures--Sharps0? 3.85 (6) 1.20.

IndicatorGoalHC?JulAugSepOctNovDecJanFebMarAprMayJunYTD % Perfection Worksite Safety Indicators Blood Borne Pathogen Exposures--Sharps0? 3.85 (6) 1.20.
CONTINUOUS QUALITY IMPROVEMENT Continuous Quality Stony Brook Medicine.

CONTINUOUS QUALITY IMPROVEMENT Continuous Quality Stony Brook Medicine.
The Healthcare Cost and Utilization Project (HCUP) Tools and Products Agency for Healthcare Research and Quality APHA CEI Session  November 2006.

The Healthcare Cost and Utilization Project (HCUP) Tools and Products Agency for Healthcare Research and Quality APHA CEI Session  November 2006.
Lessons from the AHRQ PSI Validation Pilot Project AHRQ QI Users Meeting September 10, 2008 Presenter: Patrick S. Romano, MD MPH; Professor, UC Davis Center.

Lessons from the AHRQ PSI Validation Pilot Project AHRQ QI Users Meeting September 10, 2008 Presenter: Patrick S. Romano, MD MPH; Professor, UC Davis Center.
Indun Whetsell March 6, 2015. ContributedPotential Gain/At Risk VBP $408,893$1,054,593* RRP $817,786$817,786** HAC $272,595$272,595** BCBS $1.2 million*

Indun Whetsell March 6, ContributedPotential Gain/At Risk VBP $408,893$1,054,593* RRP $817,786$817,786** HAC $272,595$272,595** BCBS $1.2 million*
Present on Admission. Requirements of Deficit Reduction Act 2005 CMS and CDC choose conditions that are: High Cost, High Volume, or both. Assigned to.

Present on Admission. Requirements of Deficit Reduction Act 2005 CMS and CDC choose conditions that are: High Cost, High Volume, or both. Assigned to.
1 Overview of Organization & Comparative Quality Data Ron Spingarn, Deputy Director Healthcare Information Division Phone:

1 Overview of Organization & Comparative Quality Data Ron Spingarn, Deputy Director Healthcare Information Division Phone:
Overview of the AHRQ QI Toolkit for Hospitals Courtney Gidengil, MD MPH Peter Hussey, PhD RAND Corporation.

Overview of the AHRQ QI Toolkit for Hospitals Courtney Gidengil, MD MPH Peter Hussey, PhD RAND Corporation.
The AHRQ Quality Indicators Melanie Chansky, MAA, Research Scientist Battelle Memorial Institute December 4, 2008.

The AHRQ Quality Indicators Melanie Chansky, MAA, Research Scientist Battelle Memorial Institute December 4, 2008.
AHRQ Quality Indicators Toolkit Tool A.2 Instructions.

AHRQ Quality Indicators Toolkit Tool A.2 Instructions.
Impact of the MS-DRGs on the AHRQ QIs

Impact of the MS-DRGs on the AHRQ QIs
Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Uses vs. Usual Care in the Hospital Setting Prepared for: Agency for Healthcare Research.

Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Uses vs. Usual Care in the Hospital Setting Prepared for: Agency for Healthcare Research.
Refinement and Validation of the AHRQ Patient Safety Indicators Developed by UC-Stanford Evidence Based Practice Center Funded by the Agency for Healthcare.

Refinement and Validation of the AHRQ Patient Safety Indicators Developed by UC-Stanford Evidence Based Practice Center Funded by the Agency for Healthcare.

Similar presentations

Ads by Google